| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2020-08-28 |
| タイトル |
|
|
タイトル |
EFFICACY AND SAFETY OF TREATMENT WITH SOFOSBUVIR PLUS RIBAVIRIN FOR HEPATITS C VIRUS GENOTYPE2 |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Hepatitis C |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
genotype2 |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
sofosbuvir |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
ribavirin |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| ID登録 |
|
|
ID登録 |
10.20569/00005119 |
|
ID登録タイプ |
JaLC |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 作成者 |
Matsuzawa, Hisanori
Ohshima, Shigetoshi
Goto, Takashi
Komatsu, Masafumi
Nakane, Kunio
Yagisawa, Hitoshi
Nakajima, Kou
Hoshino, Takao
Kuramitsu, Tomoyuki
Yoneyama, Kazuo
Fujishima, Yuukou
Watanabe, Daisuke
Kataoka, Ei
Segawa, Daisuke
Iijima, Katsunori
|
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Objective : We conducted a multicenter study in Akita Prefecture, Japan, to characterize the efficacy and safety of sofosbuvir (SOF) plus ribavirin (RBV) therapy in Japanese patients infected with hepatitis C virus (HCV) genotype 2.
Methods : All of the patients were infected with HCV genotype 2. Patients received 12 weeks of treatment with 400 mg of SOF daily plus weight-based RBV (600-1,000 mg daily).
Results : A total of 170 patients were enrolled in this study, and 167 patients were followed for 12 weeks after its completion. Among our patients, 28.2% (48/170) had liver cirrhosis (LC). Overall, 159 patients achieved a sustained virologic response for 12 weeks (SVR12), while 8 showed virologic failure. There were no significant differences in the rates of SVR12 between the chronic hepatitis (CH) and LC patients. No significant differences were noted between the CH and LC patients in the rates of any adverse events.
Conclusion : We found that SOF plus RBV treatment resulted in high rates of SVR12 with a favorable safety and tolerability profile, including patients with cirrhosis. |
|
言語 |
en |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 書誌情報 |
ja : 秋田医学
en : Akita journal of medicine
巻 47,
号 1,
p. 21-30,
発行日 2020-06-30
|
| 収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0386-6106 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AN00009294 |
| 出版者 |
|
|
出版者 |
秋田医学会 |
|
言語 |
ja |
akitai47_1(21) (631.4 kB)
